|
UGGS Pas Cherひっちぃ2015年6月18日 (Nasdaq:RPRX Free Report) announced positive top line data on its secondary hypogonadism candidate, Androxal, from a pivotal phase III study. Repros had initiated two identical, 17 week, double blind ZA 304 and ZA 305 studies to compare the safety and efficacy of Androxal with a testosterone replacement therapy (topical gel) and placebo in restoring and maintaining testicular function.The ZA 305 study was the first of the two identical pivotal studies. [参考] |
コメントはありません |